Norvatis: New study shows Elidel® provides sustained control of eczema
Treatment with ElidelO (pimecrolimus) Cream 1% provided sustained control of the symptoms associated with atopic eczema for up to 18 months in both adult and paediatric patients, according to new study results announced during the congress of the American Academy of dermatology in New Orleans, USA.
The objective of the multinational study was to evaluate long-term efficacy and safety of Elidel in paediatric and adult patients with eczema of any severity, who had previously completed a six-month core study demonstrating the effectiveness of Elidel in controlling the acute signs and symptoms of atopic eczema. The extension study included 368 of these patients, who were treated for up to 18 months. Patients experienced sustained relief of their eczema symptoms (up to 18 months) when treated with Elidel in a naturalistic setting, i.e. in a clinical study that closely replicated real life. In the core study, 79.6% of patients who had used Elidel twice-daily experienced relief from the itching (pruritis) associated with mild to moderate eczema, defined as an improvement in symptoms to absent/mild pruritus.
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
